Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX), Inc. To Present at the JMP Healthcare Conference

Investorideas.com - Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX), Inc. To Present at the JMP Healthcare Conference


Visit this company: www.biosantepharma.com

LINCOLNSHIRE, Ill. - September 22, 2010 (Investorideas.com newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the JMP Healthcare Conference being held in the New York Palace Hotel, New York City from September 27-28, 2010.


Phillip B. Donenberg, BioSante's senior vice president of finance and CFO, will speak on Monday, September 27 at 1:00 pm ET. Mr. Donenberg will provide a status update on BioSante's lead program, LibiGel® (testosterone gel), in Phase III clinical studies for the treatment of female sexual dysfunction, as well as a general overview of BioSante.


About the JMP Healthcare Conference
JMP Securities presents its fifth annual healthcare industry conference, an institutional investor forum featuring more than 100 leading publicly traded and privately held companies in the areas of biotechnology, medical devices and healthcare services and facilities.



About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.




Contact:
BioSante Pharmaceuticals
For Media:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316azachary@mckinneychicago.com
For Investors:The Trout Group LLCTricia Swanson(646) 378-2953tswanson@troutgroup.com
Visit the BPAX showcase profile at Investorideas.com Request News and Info on BPAX Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp